Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative bioavailability of Myfenax and CellCept in stable renal transplant recipients
2009-010562-31Phase 4Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mycophenolate mofetil in kidney allograft rejection and kidney transplant immunosuppression (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: AUC at steady state. Started Apr 2009; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney allograft rejectionkidney transplant immunosuppression
Beyond the preview
Go deeper on 2009-010562-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010562-31.